生酮饮食、改良阿特金斯饮食与低升糖指数饮食在儿童耐药性癫痫中的疗效:一项随机临床试验
LGIT在发作减少与不良事件较少之间呈现平衡。
要点
- MAD与LGIT均未达到预设的非劣效界值(-15个百分点)。
- LGIT不良事件显著少于KD与MAD,风险-获益需个体化决策。
核心结论
- MAD与LGIT饮食均未达到相对于KD的非劣效性标准。
- LGIT饮食在癫痫发作减少与相对较少不良事件之间呈现平衡,提示三种饮食干预的风险-获益决策需个体化。
研究设计与样本
- 患儿被随机分配接受KD、MAD或LGIT作为 ongoing 抗癫痫药物治疗的添加疗法。
- 主要结局为饮食治疗24周后MAD组与KD组、LGIT组与KD组之间癫痫发作频率的百分比变化,预设非劣效界值为-15个百分点,采用意向性分析。
主要发现
- 意向性分析中,KD与MAD组间发作减少的中位差异为-21个百分点(95%CI,-29至-3个百分点),KD与LGIT组间为-12个百分点(95%CI,-21至7个百分点),两者均突破-15个百分点的非劣效界值。
- 治疗相关不良事件在KD组(31/55[56.4%])与MAD组(33/58[56.9%])相似,但LGIT组(19/57[33.3%])显著较少。
关键数值与推荐
- 非劣效界值预设为-15个百分点。
- KD与MAD组间发作减少中位差异为-21个百分点(95%CI,-29至-3个百分点)。
- KD与LGIT组间发作减少中位差异为-12个百分点(95%CI,-21至7个百分点)。
- 不良事件发生率:KD组56.4%(31/55),MAD组56.9%(33/58),LGIT组33.3%(19/57)。
临床怎么用
- 对于儿童耐药性癫痫,KD、MAD与LGIT均可考虑作为添加治疗,但MAD与LGIT未证明非劣效于KD。
- LGIT可能提供发作减少与较少不良事件之间的平衡,临床决策需结合个体风险-获益进行个体化选择。
局限性
- 研究在印度单中心三级转诊中心进行,外推性需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The ketogenic diet (KD) has been used successfully to treat children with drug-resistant epilepsy. Data assessing the efficacy of the modified Atkins diet (MAD) and low glycemic index therapy (LGIT) diet compared with the KD are scarce. OBJECTIVE: To determine whether the MAD and LGIT diet are noninferior to the KD among children with drug-resistant epilepsy. DESIGN, SETTING, AND PARTICIPANTS: One hundred seventy children aged between 1 and 15 years who had 4 or more seizures per month, had not responded to 2 or more antiseizure drugs, and had not been treated previously with the KD, MAD, or LGIT diet were enrolled between April 1, 2016, and August 20, 2017, at a tertiary care referral center in India. EXPOSURES: Children were randomly assigned to receive the KD, MAD, or LGIT diet as additions to ongoing therapy with antiseizure drugs. MAIN OUTCOMES AND MEASURES: Primary outcome was percentage change in seizure frequency after 24 weeks of dietary therapy in the MAD cohort compared with the KD cohort and in the LGIT diet cohort compared with the KD cohort. The trial was powered to assess noninferiority of the MAD and LGIT diet compared with the KD with a predefined, noninferiority margin of -15 percentage points. Intention-to-treat analysis was used. RESULTS: One hundred fifty-eight children completed the trial: KD (n = 52), MAD (n = 52), and LGIT diet (n = 54). Intention-to-treat analysis showed that, after 24 weeks of intervention, the median (interquartile range [IQR]) change in seizure frequency (KD: -66%; IQR, -85% to -38%; MAD: -45%; IQR, -91% to -7%; and LGIT diet: -54%; IQR, -92% to -19%) was similar among the 3 arms (P = .39). The median difference, per intention-to-treat analysis, in seizure reduction between the KD and MAD arms was -21 percentage points (95% CI, -29 to -3 percentage points) and between the KD and LGIT arms was -12 percentage points (95% CI, -21 to 7 percentage points), with both breaching the noninferiority margin of -15 percentage points. Treatment-related adverse events were similar between the KD (31 of 55 [56.4%]) and MAD (33 of 58 [56.9%]) arms but were significantly less in the LGIT diet arm (19 of 57 [33.3%]). CONCLUSIONS AND RELEVANCE: Neither the MAD nor the LGIT diet met the noninferiority criteria. However, the results of this study for the LGIT diet showed a balance between seizure reduction and relatively fewer adverse events compared with the KD and MAD. These potential benefits suggest that the risk-benefit decision with regard to the 3 diet interventions needs to be individualized. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02708030.
引用
- Sondhi V, Agarwala A, Pandey RM, et al. Efficacy of Ketogenic Diet, Modified Atkins Diet, and Low Glycemic Index Therapy Diet Among Children With Drug-Resistant Epilepsy: A Randomized Clinical Trial. JAMA Pediatr. 2020. PMID: 32761191. doi:10.1001/jamapediatrics.2020.2282
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。